EUVIMEDOpdag EUVIMED
Open access

Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis

Hayder Ridha-Salman iD, Elaf Mahmood Shihab, Hasanain Kamil Hasan, Alaa Hamza Abbas, Shan Mohammed Khorsheed, Salar Ayad Fakhri

ACS Pharmacology & Translational Science · 2024-09-13 · 7 (9) · 2739-2754

DOI: 10.1021/acsptsci.4c00152 ↗

At a glance

Journal article in ACS Pharmacology & Translational Science, published online on 2024-08-02. Written by Hayder Ridha-Salman and 5 co-authors. Institution: Department of Pharmacology, College of Pharmacy, Al-Mustaqbal University, Hillah 51001, Babylon +964, Iraq. Cited 36 times so far (Crossref); 195 references. The full text is freely available in PubMed Central. Funded by: Al-Nahrain University.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Psoriasis is a chronic, inflammatory dermatosis characterized by thickened, reddened, and scaly skin lesions. Norfloxacin is a fluoroquinolone antibiotic with enhanced antioxidant, anti-inflammatory, and immunomodulatory bioactivities. The aim of this study was to figure out the possible impact of topical norfloxacin on an imiquimod-induced model of psoriasis in mice. Thirty albino-type mice were split into five distinct groups of six animals each. The control group included healthy mice that had not received any treatment. The induction group was given the vehicle 2 h after the topical imiquimod, once daily for 8 days. Two hours after receiving topical imiquimod, the treatment groups including calcipotriol, norfloxacin 2.5%, and norfloxacin 5% were given topical ointments containing calcipotriol 0.005%, norfloxacin 2.5%, and norfloxacin 5%, for 8 days. Topical norfloxacin ointment significantly reduced the severity of imiquimod-exacerbated psoriatic lesions including erythema, shiny-white scaling, and acanthosis and fixed histological abnormalities. Furthermore, imiquimod-subjected mice treated with a higher concentration of norfloxacin ointment exhibited dramatically lower skin levels of inflammation-related biomarkers like IFN-γ, TNF-α, IL-6, IL-17A, IL-23, and TGF-β but higher levels of IL-10. They also demonstrated a notable decrease in angiogenesis parameters such as VEGF and IL-8, a substantial reduction in oxidative indicators like MDA and MPO, and a considerable rise in antioxidant enzymes like SOD and CAT. This study offers novel evidence that norfloxacin may assist in controlling inflammatory dermatoses like psoriasis by minimizing the severity of psoriatic plaques, correcting histological alterations, and diminishing the production of inflammatory, oxidative, and angiogenetic parameters.

Authors and institutions

  • Department of Pharmacology, College of Pharmacy, Al-Mustaqbal University, Hillah 51001, Babylon +964, Iraq.
  • Department of Pharmacology, College of Pharmacy, Al-Esraa University, Baghdad +964, Iraq.
  • Department of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad +964, Iraq.

ORCID profiles: Hayder Ridha-Salman

Funding

  • Al-Nahrain University

Cite

APA

Ridha-Salman, H., Shihab, E. M., Hasan, H. K., Abbas, A. H., Khorsheed, S. M., & Ayad Fakhri, S. (2024). Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis. ACS Pharmacology & Translational Science, 7(9), 2739-2754. https://doi.org/10.1021/acsptsci.4c00152

Vancouver

Ridha-Salman H, Shihab EM, Hasan HK, Abbas AH, Khorsheed SM, Ayad Fakhri S. Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis. ACS Pharmacology & Translational Science. 2024;7(9):2739-2754. doi:10.1021/acsptsci.4c00152

BibTeX
@article{RidhaSalman2024,
  author = {Ridha-Salman, Hayder and Shihab, Elaf Mahmood and Hasan, Hasanain Kamil and Abbas, Alaa Hamza and Khorsheed, Shan Mohammed and Ayad Fakhri, Salar},
  title = {Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis},
  journal = {ACS Pharmacology & Translational Science},
  year = {2024},
  volume = {7},
  number = {9},
  pages = {2739--2754},
  doi = {10.1021/acsptsci.4c00152}
}
Start for free →